A Randomized Clinical Trial Using CoronaVac or BNT162b2 Vaccine as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac

Am J Respir Crit Care Med. 2022 Apr 1;205(7):844-847. doi: 10.1164/rccm.202111-2655LE.

Authors

Chris Ka Pun Mok^{1

2}, Chunke Chen^{1

2}, Karen Yiu², Tat-On Chan², Kiu Cheung Lai², Kwun Cheung Ling², Yuanxin Sun^{1

2}, David S Hui², Samuel M S Cheng³, Malik Peiris³

Affiliations

¹ Li Ka Shing Institute of Health Sciences Hong Kong Special Administrative Region, People's Republic of China.
² The Chinese University of Hong Kong Hong Kong Special Administrative Region, People's Republic of China.
³ The University of Hong Kong Hong Kong Special Administrative Region, People's Republic of China.

No abstract available

Publication types

Letter
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
BNT162 Vaccine*
COVID-19 Vaccines
Humans
Vaccines*

Substances

COVID-19 Vaccines
Vaccines
BNT162 Vaccine

Grants and funding

U01 AI151810/AI/NIAID NIH HHS/United States